IQVIA Holdings/$IQV

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About IQVIA Holdings

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

Ticker

$IQV
Sector

Primary listing

NYSE

Employees

90,000

IQVIA Holdings Metrics

BasicAdvanced
$32B
27.11
$6.92
1.32
-

What the Analysts think about IQVIA Holdings

Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.

Bulls say / Bears say

IQVIA’s Q1 2025 adjusted EPS of $2.70 and revenue of $3.83 billion exceeded Wall Street expectations of $2.63 and $3.77 billion, respectively, leading to a 2.7% increase in the stock pre-market and highlighting strong performance in its core services. (Reuters)
IQVIA raised its full-year 2025 revenue guidance to $16.0 billion–$16.4 billion, above its previous outlook of $15.73 billion–$16.13 billion, taking advantage of favorable currency moves and reflecting confidence in continued growth. (Reuters)
Contract research organizations posted better-than-expected Q2 earnings, with IQVIA reporting positive indicators of stabilizing biopharma demand that could persist into 2026, suggesting a more favorable industry environment. (Reuters)
Analysts warn that demand for clinical trials has not fully recovered, so growth in IQVIA’s core R&D Solutions segment remains muted despite a broader recovery in the sector. (Reuters)
IQVIA’s net leverage ratio was 3.40x trailing twelve-month Adjusted EBITDA as of March 31, 2025, which may limit its financial flexibility for future investments. (IQVIA Q1 2025 Press Release)
Ongoing geopolitical risks, including U.S.-China trade tensions, continue to pose threats to IQVIA’s global clinical trial supply chain, introducing uncertainty to its international operations. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

IQVIA Holdings Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IQVIA Holdings Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IQV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs